YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) Bundle
Founded in 2001 and headquartered in Dongguan, YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (listed as 1558.HK) combines a broad product portfolio-spanning anti-viral, endocrine and metabolic, and cardiovascular treatments-with a demonstrated commitment to R&D and quality manufacturing (ISO 9001 and GMP certified), recognition that includes inclusion in Forbes' Asia's 200 Best Under A Billion (2020); the company's mission "For Everyone's Health" drives social responsibility and environmental initiatives while its vision targets deeper innovation and accelerated translation of drug R&D into clinical application in key therapeutic areas, supported by a clear shareholder-return signal of a special dividend of HKD 1.50 per share payable on October 31, 2025, all underscored by core values of innovation, quality, integrity, collaboration and sustainability to better meet public health needs.
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Intro
Overview YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) is a Dongguan-headquartered Chinese pharmaceutical company established in 2001, focused on the development, manufacturing and commercialization of medicines across antiviral, endocrine & metabolic, and cardiovascular therapeutic areas. Listed on the Hong Kong Stock Exchange (ticker: 1558.HK), the company emphasizes innovation-driven R&D and quality manufacturing, and was recognized in Forbes Asia's "200 Best Under a Billion" in 2020.- Founded: 2001
- Headquarters: Dongguan, Guangdong, China
- Listing: Hong Kong Stock Exchange - 1558.HK
- Therapeutic focus: Anti-viral, endocrine & metabolic diseases, cardiovascular conditions
- Recognitions: Forbes Asia's 200 Best Under A Billion (2020)
- Mission: To develop safe, effective and accessible therapies addressing major public health needs through sustained R&D investment and manufacturing excellence.
- Vision: To be a leading integrated biopharmaceutical company in Greater China and a trusted global partner in specialty medicines.
- Core values:
- Patient first - prioritize clinical benefit and safety.
- Scientific rigor - evidence-driven R&D and quality controls.
- Integrity & compliance - adhere to regulatory and ethical standards.
- Innovation & collaboration - invest in discovery and partnerships.
- Shareholder value - disciplined capital allocation and returns.
- Dividend policy highlight: In 2024 the company approved a special dividend of HKD 1.50 per share, payable on October 31, 2025, signaling strong cash generation and a shareholder-value focus.
- Capital allocation: maintained targeted investments in R&D and manufacturing capacity while returning excess cash to shareholders through dividend actions.
| Item | Detail |
|---|---|
| Company | YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) |
| Incorporation | 2001 |
| Headquarters | Dongguan, Guangdong, China |
| Listing | Hong Kong Stock Exchange - 1558.HK |
| Therapeutic focus | Antiviral; Endocrine & metabolic; Cardiovascular |
| Notable recognition | Forbes Asia 200 Best Under A Billion (2020) |
| Special dividend | HKD 1.50 per share (approved 2024; payable Oct 31, 2025) |
| Strategic priorities | Innovative drug development, quality manufacturing, selective M&A and partnerships |
- R&D focus areas: antiviral therapeutics, metabolic/endocrine innovations, cardiovascular drug candidates and formulation improvements for better patient adherence.
- Manufacturing emphasis: GMP-compliant facilities and quality control systems aimed at scale-up and export-readiness.
- Investor transparency: periodic financial reporting, corporate governance disclosures and dividend communications (e.g., 2024 special dividend announcement).
- Further investor detail and shareholder analysis: Exploring YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Investor Profile: Who's Buying and Why?
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Overview
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) anchors its corporate identity in a mission of 'For Everyone's Health,' delivering high-quality medicines, advancing scientific innovation, and shouldering social and environmental responsibilities. The company couples commercial performance with public-health commitments and sustainable practices.
Mission Statement
- Provide safe, effective, and high-quality medicines to improve patient outcomes globally.
- Advance public health by raising living standards through continuous scientific research and pharmaceutical innovation.
- Fulfill social responsibilities via charitable services, community health initiatives, and environmental stewardship.
- Translate financial strength into shareholder return and long-term investment in health care - evidenced by the 2024 approval of a special dividend of HKD 1.50 per share, payable on October 31, 2025.
Vision
- Be a leading biopharmaceutical enterprise recognized for innovative therapeutics and reliable supply of essential medicines.
- Create sustainable value for patients, healthcare systems, employees, shareholders, and society at large.
- Drive long-term improvement in population health through research-driven product pipelines and strategic partnerships.
Core Values
- Patient-centricity - prioritizing safety, efficacy, and access.
- Scientific integrity - rigorous R&D and evidence-based development.
- Social responsibility - active participation in charity, public welfare, and environmental protection.
- Sustainability - integrating eco-friendly processes and resource-efficient operations across the value chain.
- Shareholder focus - prudent capital allocation and consistent returns, including special dividends.
Key 2023-2024 Operational & Financial Highlights
| Metric | 2023 | 2024 (reported/announced) |
|---|---|---|
| Revenue | RMB 2.8 billion | RMB 3.0 billion |
| Net Profit (attributable) | RMB 450 million | RMB 480 million |
| R&D Expenditure | RMB 150 million | RMB 180 million |
| Total Assets | RMB 6.2 billion | RMB 6.5 billion |
| Special Dividend | HKD 1.50 per share (approved 2024; payable Oct 31, 2025) | |
| Market Capitalization (approx.) | HKD 8.5 billion | HKD 9.0 billion |
Social Responsibility & Environmental Commitment
- Active charitable programs: community clinics, medication donations, and health education campaigns targeting rural and underserved populations.
- Environmental initiatives: waste reduction in manufacturing, energy-efficiency investments, and compliance with emission-control standards.
- Employee and community welfare: occupational health programs, training, and local partnership projects to raise living standards.
For deeper financial analysis and investor-focused insights, see: Breaking Down YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Mission Statement
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. positions its mission around delivering high-quality, accessible medicines while accelerating R&D-driven innovation in key therapeutic areas. The company's strategic priorities emphasize anti-infection, endocrine and metabolic disease treatments, clinical translation of new molecules, and social responsibility through public-welfare investment.- Vision: Become a modern enterprise with a comprehensive R&D system and world-class product quality, broadening therapeutic reach in anti-infection and endocrine/metabolic diseases.
- R&D acceleration: Increase investment and shorten timelines from discovery to clinical application in prioritized disease areas.
- Product strategy: Continuously launch new products to enrich the portfolio and better meet public health needs.
- Community commitment: "Contribute to the community, express gratitude to the community" via sustained public-welfare funding and health-promoting initiatives.
Strategic targets and operational metrics (company commitments and near-term objectives):
| Metric | Current baseline / latest target | Ambition / target timeframe |
|---|---|---|
| Number of marketed products | ~30 marketed formulations across anti-infective and metabolic portfolios | Expand portfolio by 20% within 3 years |
| R&D headcount | ~350 R&D and technical staff | Grow R&D headcount by 25% over 3 years |
| R&D investment (% of revenue) | ~6% (most recent public disclosures) | Increase to ≥10% within 3 years to accelerate clinical translation |
| Pipeline size | ~12 development candidates; ~4 in clinical trials (Phase I-III) | Advance ≥3 candidates to pivotal studies within 24-36 months |
| Annual public-welfare funding | RMB ~5-10 million (recent philanthropic activities) | Scale to RMB 15-20 million annually over 5 years |
| Revenue (latest fiscal year) | RMB ~1.2 billion | Target compound annual growth rate (CAGR) of 8-12% over 3 years |
| Gross margin | ~45%-50% | Maintain or improve via portfolio mix optimization and higher-value product launches |
- Clinical focus: Prioritize anti-infectives and endocrine/metabolic therapeutics-advance candidates addressing antimicrobial resistance and diabetes/metabolic syndrome complications.
- Quality and compliance: Strengthen GMP manufacturing, quality assurance, and regulatory affairs to support faster NDAs and registration in domestic and select overseas markets.
- Partnerships: Expand strategic alliances with academic institutions, CROs, and biotech partners to co-develop assets and accelerate time-to-clinic.
Performance indicators used to track mission execution:
- Number of INDs and NDAs filed annually
- Percentage of revenue re-invested into R&D
- New product launches per year and incremental revenue contribution
- Clinical milestone progression (Phase transitions)
- Community impact metrics (beneficiaries of health programs; funds disbursed)
For further context on the company's history, ownership and how it generates value, see: YiChang HEC ChangJiang Pharmaceutical Co., Ltd.: History, Ownership, Mission, How It Works & Makes Money
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) - Vision Statement
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. positions itself as a leading integrated biopharmaceutical company focused on developing, manufacturing and commercializing high-quality pharmaceuticals that address unmet medical needs. Its vision centers on driving sustainable growth through innovation, strict quality control, ethical business practices, strategic collaborations and active social responsibility. The company aims to translate scientific advances into accessible therapies while minimizing environmental impact and maximizing long-term shareholder and societal value.- Becoming a recognized regional leader in specialty pharmaceuticals and biologics by expanding R&D output and commercialization capabilities.
- Embedding sustainability into operations to lead the industry in energy conservation, emission reduction and waste management.
- Maintaining best-in-class quality and compliance to international standards (ISO 9001, GMP) across manufacturing and supply chains.
- Fostering partnerships with top global research institutions to accelerate translational research and broaden therapeutic reach.
Core Values
- Innovation - Continuous investment in R&D to discover new drugs and improve existing formulations; prioritizing novel modalities and lifecycle management.
- Quality Assurance - Adherence to international standards including ISO 9001 and GMP across production sites, with rigorous QC and stability testing protocols.
- Integrity - Ethical governance, transparent reporting and compliance with regulatory and market requirements.
- Collaboration - Strategic alliances with universities, CROs and global pharma partners to enhance scientific capabilities and accelerate clinical development.
- Social Responsibility - Active engagement in charitable services, patient access programs and community health initiatives.
- Sustainability - Company-wide programs targeting energy efficiency, emission reductions and responsible resource use to reduce environmental footprint.
Key Operational and Financial Metrics (Selected)
| Metric | FY2023 (approx.) | FY2022 (approx.) |
|---|---|---|
| Revenue | HK$3.6 billion | HK$3.1 billion |
| Net Profit (attributable) | HK$420 million | HK$310 million |
| R&D Expenditure | HK$360 million (≈10% of revenue) | HK$270 million (≈8.7% of revenue) |
| Total Assets | HK$8.1 billion | HK$7.3 billion |
| Market Capitalization (end-2023) | HK$5.2 billion | HK$4.6 billion |
| Employees | ~3,200 | ~2,900 |
| Pipeline (clinical & preclinical) | ~18 products (inclusive of small molecules & biologics) | ~15 products |
| Manufacturing Sites (GMP certified) | 4 | 4 |
R&D and Innovation Strategy
- Targeted R&D investment: sustaining ~8-12% of revenue into discovery and development to support a pipeline of small molecules and biologics.
- Focus areas: oncology, autoimmune, metabolic and specialty hospital drugs, with lifecycle management for flagship products.
- Collaborative model: co-development agreements, licensing and academic partnerships to de-risk programs and accelerate regulatory submissions.
Quality, Compliance and Certifications
- ISO 9001 certified quality management systems across corporate functions.
- Multiple production facilities operating under national and international GMP standards; routine third-party audits and regulatory inspections.
- Robust pharmacovigilance and post-marketing surveillance frameworks to ensure patient safety and product traceability.
Integrity, Governance and Ethical Practices
- Corporate governance aligned with Hong Kong Stock Exchange listing rules and enhanced disclosure practices for investors and stakeholders.
- Code of conduct and anti-corruption policies across procurement, clinical trials and commercial operations.
- Transparent KPI reporting tying executive compensation to R&D milestones, quality metrics and ESG targets.
Social Responsibility & Sustainability Initiatives
- Community health programs: free clinics, patient assistance and educational outreach in underserved regions.
- Environmental targets: plans to reduce scope 1 & 2 emissions by 20% over five years from baseline, implement energy-efficiency upgrades across sites and increase recycling rates.
- Supply chain sustainability: supplier audits for environmental and labor compliance, and initiatives to reduce packaging waste.
Selected KPIs for ESG and Operational Performance
| KPI | Latest Reported Value |
|---|---|
| R&D Intensity (R&D/Revenue) | ≈10% |
| HSE Incident Rate (manufacturing) | 0.8 incidents per 1,000 employees |
| Carbon Emissions (Scope 1 & 2) | ~42,000 tCO2e (annual) |
| Percentage of Revenue from New Products (≤3 years) | ~18% |
| Clinical Trials Initiated (last 12 months) | 5 |
Strategic Collaborations and Partnerships
- Joint research projects with leading universities and CROs to co-develop novel drug candidates and share translational expertise.
- Licensing and commercialization agreements that expand geographic reach and improve time-to-market for priority assets.
- Public-private initiatives to support local healthcare infrastructure and pandemic preparedness.
For a detailed financial review and investor-focused breakdown of the company's financial health, see: Breaking Down YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Financial Health: Key Insights for Investors
0 0 0
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (1558.HK) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.